[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RS63572B1 - Urat1 inhibitor i njegova upotreba - Google Patents

Urat1 inhibitor i njegova upotreba

Info

Publication number
RS63572B1
RS63572B1 RS20220866A RSP20220866A RS63572B1 RS 63572 B1 RS63572 B1 RS 63572B1 RS 20220866 A RS20220866 A RS 20220866A RS P20220866 A RSP20220866 A RS P20220866A RS 63572 B1 RS63572 B1 RS 63572B1
Authority
RS
Serbia
Prior art keywords
urat1 inhibitor
urat1
inhibitor
Prior art date
Application number
RS20220866A
Other languages
English (en)
Inventor
Dongfang Shi
Changjin Fu
Xi Cheng
Jianghua Zhu
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62172162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63572(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority claimed from PCT/CN2017/111013 external-priority patent/WO2018090921A1/zh
Publication of RS63572B1 publication Critical patent/RS63572B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RS20220866A 2016-11-16 2017-11-15 Urat1 inhibitor i njegova upotreba RS63572B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201611008935 2016-11-16
CN201711115037.9A CN108084186B (zh) 2016-11-16 2017-11-13 Urat1抑制剂及其应用
PCT/CN2017/111013 WO2018090921A1 (zh) 2016-11-16 2017-11-15 Urat1抑制剂及其应用
EP17872538.8A EP3543240B1 (en) 2016-11-16 2017-11-15 Urat1 inhibitor and use thereof

Publications (1)

Publication Number Publication Date
RS63572B1 true RS63572B1 (sr) 2022-10-31

Family

ID=62172162

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220866A RS63572B1 (sr) 2016-11-16 2017-11-15 Urat1 inhibitor i njegova upotreba

Country Status (18)

Country Link
US (2) US10875865B2 (sr)
EP (1) EP3543240B1 (sr)
JP (1) JP6925054B2 (sr)
KR (1) KR102263441B1 (sr)
CN (1) CN108084186B (sr)
AU (1) AU2017360465B2 (sr)
CA (1) CA3043942C (sr)
DK (1) DK3543240T3 (sr)
ES (1) ES2923177T3 (sr)
HR (1) HRP20221151T1 (sr)
HU (1) HUE059778T2 (sr)
IL (1) IL266587B2 (sr)
MX (1) MX2019005565A (sr)
MY (1) MY197564A (sr)
PL (1) PL3543240T3 (sr)
PT (1) PT3543240T (sr)
RS (1) RS63572B1 (sr)
TW (1) TWI668213B (sr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066680C (en) * 2017-05-26 2022-04-12 Dongfang Shi Urat1 inhibitor for increasing uric acid excretion
CN111615515B (zh) * 2018-01-19 2023-11-24 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN108623586B (zh) * 2018-07-16 2021-03-16 广东工业大学 一种咪唑并含氮杂环类化合物的合成方法与应用
CN109432079B (zh) * 2018-09-07 2021-06-22 江苏康缘药业股份有限公司 一种化合物在制备用于痛风的药物中的应用
CN111763180B (zh) * 2019-04-02 2023-06-09 中国医学科学院药物研究所 苯并氮杂环类化合物及其制法和药物用途
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN111533718B (zh) * 2020-05-12 2022-05-17 浙江海洲制药有限公司 一种制备苯溴马隆的方法
CN112250688B (zh) * 2020-10-15 2022-11-04 天津科技大学 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用
CN112877295A (zh) * 2021-02-26 2021-06-01 华南理工大学 一种urat1抑制剂体外活性筛选的细胞模型及其构建方法与筛选方法
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117128A (en) * 1976-08-03 1978-09-26 Smithkline Corporation Sulfonyl benzofurans and benzothiophenes having coronary vasodilator activity
NZ193926A (en) 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2502622A1 (fr) * 1981-03-25 1982-10-01 Synthelabo Derives d'imidazo (1,2-a) pyrimidines, leur preparation et leur application en therapeutique
US5175184A (en) * 1982-10-19 1992-12-29 Kotobuki Seiyaku Company Limited Benzothiophene derivatives and antihyperuricemia thereof
JPS5973579A (ja) * 1982-10-19 1984-04-25 Kotobuki Seiyaku Kk ベンゾフラン又はベンゾチオフェン誘導体,この化合物を有効成分とする尿酸排泄剤及びその製造方法
FR2594438B1 (fr) * 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
JP2002514636A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション インスリン抵抗性または高血糖症の治療に有用なフェニルオキソ−酢酸類
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
KR20040030818A (ko) * 2001-07-20 2004-04-09 카로 바이오 아베 심방 세동의 치료에 있어서의 벤조 퓨란 및 이들의 용도
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN102015726B (zh) 2008-03-31 2014-07-23 C&C新药研究所 杂环衍生物
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
EP2900237A1 (en) * 2012-09-25 2015-08-05 Novartis AG Compounds for use in gastric complication
RU2721844C2 (ru) * 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
CA2980484C (en) * 2015-03-24 2019-11-26 Shanghai Yingli Pharmaceutical Co., Ltd Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof
CN106065010B (zh) * 2015-04-23 2019-01-01 镇江新元素医药科技有限公司 用于治疗或预防高尿酸血症或痛风的化合物
SG11201802010QA (en) * 2015-09-10 2018-04-27 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd A group of compounds used for the treatment or prevention of hyperuricemia or gout
CN108727267B (zh) * 2017-05-26 2022-05-13 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用

Also Published As

Publication number Publication date
CN108084186B (zh) 2021-06-25
USRE50083E1 (en) 2024-08-20
IL266587A (en) 2019-07-31
EP3543240A1 (en) 2019-09-25
US20200062763A1 (en) 2020-02-27
EP3543240A4 (en) 2020-05-06
MX2019005565A (es) 2019-10-30
AU2017360465B2 (en) 2021-02-04
DK3543240T3 (da) 2022-10-10
HUE059778T2 (hu) 2022-12-28
KR102263441B1 (ko) 2021-06-09
PL3543240T3 (pl) 2022-10-24
CA3043942C (en) 2021-11-02
JP2020503263A (ja) 2020-01-30
HRP20221151T1 (hr) 2022-11-25
CN108084186A (zh) 2018-05-29
TWI668213B (zh) 2019-08-11
CA3043942A1 (en) 2018-05-24
US10875865B2 (en) 2020-12-29
KR20190077083A (ko) 2019-07-02
EP3543240B1 (en) 2022-07-06
IL266587B2 (en) 2023-06-01
PT3543240T (pt) 2022-08-25
AU2017360465A1 (en) 2019-06-06
MY197564A (en) 2023-06-23
ES2923177T3 (es) 2022-09-26
TW201819364A (zh) 2018-06-01
JP6925054B2 (ja) 2021-08-25

Similar Documents

Publication Publication Date Title
HK1243072A1 (zh) 布羅莫結構域抑制劑及其用途
HK1258689A1 (zh) 氨基噻唑化合物及其用途
GB201605126D0 (en) Inhibitors and their uses
IL270330B (en) Beta-lactamase inhibitors and their uses
PT3543240T (pt) Inibidor de urat1 e utilização deste
IL264258B (en) Diazahetero-bicyclic substituted compounds and their use
IL264813B (en) 2-oxo-imidazopyridines and their use
EP3336091A4 (en) IRAQ4 INHIBITOR AND ITS USE
EP3572400C0 (en) EZH2 INHIBITOR AND ITS USE
PT3621694T (pt) Inibidores de lrrc33 e sua utilização
HUE063848T2 (hu) LSD1 gátlók és gyógyászati alkalmazásaik
EP3336090A4 (en) INHIBITOR OF IRAQ4 AND ITS USE
IL263949A (en) Complement inhibitors and their uses
IL267238A (en) The paranase inhibitors and their use
HK1250926A1 (zh) 抑制劑及其應用
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
HK1255029A1 (zh) 明膠酶抑制劑及其用途
EP3551632C0 (en) SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
IL267243A (en) The paranase inhibitors and their use
IL265617B (en) 1-phenylpropanone compounds and their use
IL247872A0 (en) stat5 inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses